Abstract
Background: Subtilisin Kexin Isozyme-1 (SKI-1)/Site1Protease (S1P) is a Ca+2-dependent membrane bound pyrolysin-type serine protease of mammalian subtilase super family Proprotein Convertases (PCs)/Proprotein Convertase Subtilisin Kexins (PCSKs). It cleaves precursor proteins at the carboxy terminus of a non basic amino acid characterized by the sequence Arg/Lys--Φ-Leu/Ser/Thr↓, where = any amino acid except Cys, Φ = the alkyl side chain containing hydrophobic amino acid. SKI-1 cleaves pro-BDNF, pro- SREBP2, pro-ATF6, pro-somatostatin and viral glycoproteins to generate their active forms. As a result SKI-1 plays important roles in cartilage development, bone mineralization, cholesterol metabolism, fatty acid synthesis and infections caused by Arina viruses of hemorrhagic type. Interest has grown to develop inhibitors of SKI-1 that may find useful therapeutic and biochemical applications.
Objective: Our objective is to develop small molecule inhibitors of SKI-1/S1P and study their kinetic and biochemical properties.
Results: Peptide analogs were designed by inserting a protease resistant methylene-oxy (-CH2-O-) pseudoamide function at the cleavage site of 251Asp-Ile-Tyr-Ile-Ser-Arg-Arg-Leu-Leu↓Gly-Thr-Phe-Thr263, derived from SKI-1 processing site of Lassa virus glycoprotein. The synthesis was conducted by substituting Leu-Gly with previously made Leu-CH2-O-Gly. Flexible linear and conformationally constrained circular and disulphide bridged cyclic peptides were prepared by solid phase method. Circular and cyclic peptides inhibited SKI-1 more potently (Ki∼14-20 μM) than the corresponding acyclic peptide (Ki7sim;51 μM). They also blocked SKI-1-mediated processing of pro-h(human)SREBP2 into its mature form in HepG2 cells. Circular pseudopeptides designed from hATF6 and hSREBP2 also inhibited SKI-1. This is the first report of circular and cyclic Ψ(CH2-O) containing peptides as SKI-1 inhibitors with potential therapeutic applications in cholesterol synthesis.
Keywords: Subtilisin Kexin Isozyme-1 (SKI-1), Site 1 Protease (S1P), Methylene-oxy pseudopeptides, Enzyme inhibitors, Intramolecularly quenched fluorogenic peptide, Circular peptide, Disulfide bridged cyclic peptide, Inhibition constant (Ki), Proprotein processing
Current Medicinal Chemistry
Title: Novel Circular, Cyclic and Acyclic ψ(CH2O) Containing Peptide Inhibitors of SKI- 1/S1P: Synthesis, Kinetic and Biochemical Evaluations
Volume: 18 Issue: 18
Author(s): S. Majumdar, A. Chen, H. Palmer-Smith and A. Basak
Affiliation:
Keywords: Subtilisin Kexin Isozyme-1 (SKI-1), Site 1 Protease (S1P), Methylene-oxy pseudopeptides, Enzyme inhibitors, Intramolecularly quenched fluorogenic peptide, Circular peptide, Disulfide bridged cyclic peptide, Inhibition constant (Ki), Proprotein processing
Abstract: Background: Subtilisin Kexin Isozyme-1 (SKI-1)/Site1Protease (S1P) is a Ca+2-dependent membrane bound pyrolysin-type serine protease of mammalian subtilase super family Proprotein Convertases (PCs)/Proprotein Convertase Subtilisin Kexins (PCSKs). It cleaves precursor proteins at the carboxy terminus of a non basic amino acid characterized by the sequence Arg/Lys--Φ-Leu/Ser/Thr↓, where = any amino acid except Cys, Φ = the alkyl side chain containing hydrophobic amino acid. SKI-1 cleaves pro-BDNF, pro- SREBP2, pro-ATF6, pro-somatostatin and viral glycoproteins to generate their active forms. As a result SKI-1 plays important roles in cartilage development, bone mineralization, cholesterol metabolism, fatty acid synthesis and infections caused by Arina viruses of hemorrhagic type. Interest has grown to develop inhibitors of SKI-1 that may find useful therapeutic and biochemical applications.
Objective: Our objective is to develop small molecule inhibitors of SKI-1/S1P and study their kinetic and biochemical properties.
Results: Peptide analogs were designed by inserting a protease resistant methylene-oxy (-CH2-O-) pseudoamide function at the cleavage site of 251Asp-Ile-Tyr-Ile-Ser-Arg-Arg-Leu-Leu↓Gly-Thr-Phe-Thr263, derived from SKI-1 processing site of Lassa virus glycoprotein. The synthesis was conducted by substituting Leu-Gly with previously made Leu-CH2-O-Gly. Flexible linear and conformationally constrained circular and disulphide bridged cyclic peptides were prepared by solid phase method. Circular and cyclic peptides inhibited SKI-1 more potently (Ki∼14-20 μM) than the corresponding acyclic peptide (Ki7sim;51 μM). They also blocked SKI-1-mediated processing of pro-h(human)SREBP2 into its mature form in HepG2 cells. Circular pseudopeptides designed from hATF6 and hSREBP2 also inhibited SKI-1. This is the first report of circular and cyclic Ψ(CH2-O) containing peptides as SKI-1 inhibitors with potential therapeutic applications in cholesterol synthesis.
Export Options
About this article
Cite this article as:
Majumdar S., Chen A., Palmer-Smith H. and Basak A., Novel Circular, Cyclic and Acyclic ψ(CH2O) Containing Peptide Inhibitors of SKI- 1/S1P: Synthesis, Kinetic and Biochemical Evaluations, Current Medicinal Chemistry 2011; 18 (18) . https://dx.doi.org/10.2174/092986711796011265
DOI https://dx.doi.org/10.2174/092986711796011265 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Use of Speech Analyses within a Mobile Application for the Assessment of Cognitive Impairment in Elderly People
Current Alzheimer Research Targeting Neurotrophin Receptors in the Central Nervous System
CNS & Neurological Disorders - Drug Targets Liquid Filled Hard Shell Capsules: Current Drug Delivery Influencing Pharmaceutical Technology
Current Drug Delivery Riluzole Inhibits Proliferation, Migration and Cell Cycle Progression and Induces Apoptosis in Tumor Cells of Various Origins
Anti-Cancer Agents in Medicinal Chemistry Reflection on Existence of Neural and Non-Neural Pathway for Nose- to- Brain Using a Novel Formulation of an Anticholinesterase Piperidine Derivative
Current Nanoscience BACE1 Structure and Function in Health and Alzheimers Disease
Current Alzheimer Research Hypoxia as an Initiator of Neuroinflammation: Microglial Connections
Current Neuropharmacology Preclinical Studies and Clinical Trials with Mesenchymal Stem Cell for Demyelinating Diseases: A Systematic Review
Current Stem Cell Research & Therapy Modulation and Absorption of Xenobiotics: The Synergistic Role of CYP450 and P-gp Activities in Cancer and Neurodegenerative Disorders
Current Drug Metabolism Editorial (Thematic Issue: New Approaches to the Treatment of Alzheimer's Disease)
Current Topics in Medicinal Chemistry Editorial [Hot topic: Endocannabinoid Signaling and Neuroinflammatory Diseases (Executive Editor: Mauro Maccarrone)]
Current Pharmaceutical Design Cutting-edge Patents in Alzheimers Disease Drug Discovery: Anticipation of Potential Future Treatments
Recent Patents on CNS Drug Discovery (Discontinued) Focus on the Correlations between Alzheimer’s Disease and Type 2 Diabetes
Endocrine, Metabolic & Immune Disorders - Drug Targets Ongoing Electroencephalographic Activity Associated with Cortical Arousal in Transgenic PDAPP Mice (hAPP V717F)
Current Alzheimer Research Targeting Oxidative Stress Component in the Therapeutics of Epilepsy
Current Topics in Medicinal Chemistry Poly(ADP-Ribose) Polymerase Inhibitors: New Pharmacological Functions and Potential Clinical Implications
Current Pharmaceutical Design Neuroimaging Findings Related to Behavioral Disturbances in Alzheimer's Disease: A Systematic Review
Current Alzheimer Research Lambert-Eaton Myasthenic Syndrome: A Very Rare and Tortuously Exasperating Facet of Pre-Synaptic Disorder of Neuromuscular Junction
Current Immunology Reviews (Discontinued) Minocycline: Neuroprotective Mechanisms in Parkinsons Disease
Current Pharmaceutical Design Transgenic Mouse Models of Parkinsons Disease and Huntingtons Disease
CNS & Neurological Disorders - Drug Targets